SUD 20.0% 0.6¢ suda pharmaceuticals ltd

MMV

  1. 393 Posts.
    lightbulb Created with Sketch. 11
    Looking  at the MMV Website Protophama Ltd which is effectively partnered with SUDA in relation to artimist, cracks a mention as part of the global malaria portfolio. Table does state that artimist and numerous other products are not part of the MMV portfolio but the fact that it has made the list is a positive sign. Artimist is one of 4 products targeting severe malaria as categorized by MMV. It would also appear that artimist is a lot further along the research path than a number of other companies. The link below takes you to the site. The second and third  attachments mention Protopharma -Artimist.

    http://www.mmv.org/research-development/rd-portfolio
 
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.